Vera Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.02 Insider Own0.10% Shs Outstand24.23M Perf Week1.45%
Market Cap387.39M Forward P/E- EPS next Y-3.40 Insider Trans- Shs Float11.33M Perf Month-2.11%
Income-45.00M PEG- EPS next Q-0.80 Inst Own89.60% Short Float6.48% Perf Quarter-38.98%
Sales- P/S- EPS this Y41.20% Inst Trans33.90% Short Ratio7.74 Perf Half Y-47.79%
Book/sh5.55 P/B2.51 EPS next Y-27.70% ROA-41.10% Target Price42.67 Perf Year-0.78%
Cash/sh5.43 P/C2.57 EPS next 5Y- ROE-47.10% 52W Range12.28 - 37.11 Perf YTD-47.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.41% Beta-
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low13.55% ATR1.16
Employees18 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)46.85 Volatility7.90% 8.27%
OptionableNo Debt/Eq0.04 EPS Q/Q-206.40% Profit Margin- Rel Volume1.25 Prev Close13.27
ShortableYes LT Debt/Eq0.04 EarningsMay 16 BMO Payout- Avg Volume94.88K Price13.95
Recom1.70 SMA201.83% SMA50-12.41% SMA200-30.93% Volume116,249 Change5.12%
May-02-22Initiated H.C. Wainwright Buy $35
Apr-19-22Initiated Wedbush Outperform $32
Jun-18-22 08:20AM  
Jun-04-22 02:30PM  
Jun-02-22 07:30AM  
May-20-22 04:05PM  
May-16-22 07:30AM  
May-05-22 04:05PM  
May-03-22 04:33PM  
May-02-22 07:06PM  
Apr-12-22 07:30AM  
Mar-24-22 06:30AM  
Mar-21-22 07:30AM  
Mar-17-22 07:30AM  
Mar-01-22 07:30AM  
Feb-22-22 05:29AM  
Feb-14-22 04:01PM  
Feb-10-22 08:46AM  
Feb-07-22 05:24PM  
Jan-18-22 07:30AM  
Jan-04-22 07:30AM  
Dec-20-21 07:26PM  
Dec-17-21 07:54AM  
Dec-14-21 07:30AM  
Nov-10-21 04:15PM  
Nov-04-21 04:05PM  
Oct-13-21 07:30AM  
Sep-09-21 07:30AM  
Sep-07-21 04:58AM  
Aug-18-21 02:45PM  
Aug-16-21 07:30AM  
Jul-14-21 07:30AM  
Jun-24-21 07:15AM  
Jun-15-21 11:37AM  
May-27-21 04:05PM  
May-14-21 03:40PM  
May-13-21 08:52PM  
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Curley JoanneChief Development OfficerJun 22Option Exercise6.371,2397,89625,233Jun 23 06:49 PM
Curley JoanneChief Development OfficerJun 22Sale15.011,54523,19823,688Jun 23 06:49 PM
Curley JoanneChief Development OfficerJun 17Option Exercise3.904,68718,25628,535Jun 21 08:16 PM
Curley JoanneChief Development OfficerJun 17Sale15.045,88788,56523,994Jun 21 08:16 PM
Grant SeanChief Financial OfficerJun 15Buy13.605,00068,0042,816Jun 16 04:06 PM
Curley JoanneChief Development OfficerMay 31Option Exercise6.374002,54925,594Jun 02 04:06 PM
Curley JoanneChief Development OfficerMay 31Sale15.224006,08625,194Jun 02 04:06 PM
Longitude Capital Partners IV,10% OwnerFeb 10Buy15.00333,3334,999,9953,429,927Apr 05 07:24 AM
ENRIGHT PATRICK GDirectorFeb 10Buy15.00333,3334,999,9953,429,927Apr 05 07:22 AM
Sofinnova Venture Partners X, 10% OwnerFeb 10Buy15.00266,6663,999,9903,181,442Feb 14 06:17 PM